Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea
· Delayed Price · Currency is KRW 83,000
-2,600 (-3.04%)
At close: Mar 9, 2026
KRX:185750 Revenue
Chong Kun Dang Pharmaceutical had revenue of 429.82B KRW in the quarter ending September 30, 2025, with 4.13% growth. This brings the company's revenue in the last twelve months to 1.68T, up 0.32% year-over-year. In the year 2024, Chong Kun Dang Pharmaceutical had annual revenue of 1.59T, down -4.97%.
Revenue (ttm)
1,680.99B
Revenue Growth
+0.32%
P/S Ratio
0.65
Revenue / Employee
746.11M
Employees
2,253
Market Cap
1,093.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,586.43B | -82.97B | -4.97% |
| Dec 31, 2023 | 1,669.40B | 181.06B | 12.17% |
| Dec 31, 2022 | 1,488.34B | 144.79B | 10.78% |
| Dec 31, 2021 | 1,343.56B | 40.55B | 3.11% |
| Dec 31, 2020 | 1,303.01B | 223.67B | 20.72% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ildong Pharmaceutical | 575.66B |
| Daewoong | 2,055.93B |
| DongKook Pharmaceutical | 894.93B |
| Boryung | 1,028.99B |
| Huons Global | 825.44B |
| JW Pharmaceutical | 764.21B |
| GC Biopharma | 1,934.38B |
| Dong-A Socio Holdings | 1,404.83B |